Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease: a systematic review and meta-analysis.

Chu-Hsuan ShiauLi-Yun TsauChih-Chin KaoYu-Ching PengChyi Huey Bai Jeng-Cheng Wu Wen-Hsuan Hou

Published in: International urology and nephrology (2023)

For CKD patients, no matter diabetic or non-diabetic, our study showed potential renoprotective effects favoring SGLT2is in overall and long-term phase, and in patients with macroalbuminuria or stage 4 CKD. However, only slight increased risk of adverse effects among the SGLT2is group is observed. Therefore, we concluded that in CKD patients, prescribing SGLT2is was safe and had renal benefits.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
primary care
peritoneal dialysis
prognostic factors
climate change
diabetic nephropathy
adverse drug
human health